Showing results (21-30 of 447) with videos related to
Sort By:
Pageof 45
Cardio-Oncology (London, England)|January 9, 2025
Safety and efficacy of immune checkpoint inhibitors in patients with pre-treatment reduced left ventricular functionMaor Tzuberi, Rafael Y Brzezinski, Nir Flint, et al.Cardio-Oncology (London, England)|December 30, 2024
Assessment of cardio-oncology knowledge and practice among healthcare providers in Saudi Arabia: a comprehensive nationwide surveyHisham A Badreldin, Nada Alsuhebany, Lama Alfehaid, et al.Cardio-Oncology (London, England)|December 19, 2024
Challenges in the implementation of cardio-oncology trials: lessons learnt from investigating statins in the prevention of anthracycline cardiotoxicityJohn Lee, Sean Tan, Satish RamkumarCardio-Oncology (London, England)|December 5, 2024
Thrombo-inflammation linking androgen suppression with cardiovascular risk in patients with prostate cancerAntonia Beitzen-Heineke, David R Wise, Jeffrey S BergerCardio-Oncology (London, England)|November 28, 2024
A strain-guided trial of cardioprotection in early-stage breast cancer patients on anti-HER2 therapy (PROTECT HER2)Fei Fei Gong, Eli Grunblatt, Woo Bin Voss, et al.Cardio-Oncology (London, England)|October 16, 2024
Recurrent melanoma 25 years after initial diagnosis, presenting as metastatic disease early after heart transplantationGal Rubinstein, Benjamin Izar, Diana E McDonnell, et al.Cardio-Oncology (London, England)|October 15, 2024
Expect the unexpected: fulminant myocardial cytotoxic Injury from TrabectedinAnnie J Tsay, Mohan Satish, Elizabeth Corley, et al.Cardio-Oncology (London, England)|October 11, 2024
Comparison of heart failure risk assessment tools among cancer survivorsCheng Hwee Soh, Thomas H MarwickCardio-Oncology (London, England)|October 4, 2024
Dexrazoxane prevents vascular toxicity in doxorubicin-treated miceDustin N Krüger, Matthias Bosman, Emeline M Van Craenenbroeck, et al.Cardio-Oncology (London, England)|November 10, 2024
Venous thromboembolism is associated with increased all-cause mortality in ALK-positive non-small cell lung cancerMagdalena Zaborowska-Szmit, Sebastian Szmit, Marta Olszyna-Serementa, et al.Pageof 45